Allogene Therapeutics

SOUTH SAN FRANCISCO, CA · Founded 2017 · Biotech · Public

Allogeneic CAR-T cell therapy platform with multiplex gene-engineering and gene-editing capabilities for cancer and autoimmune diseases

Claim this profile

Follows are private to you and power your alerts

Updated · allogene.com

Sector
Biotech
Headquarters
SOUTH SAN FRANCISCO, CA
Founded
2017
Latest Form D
$412M, Apr 2018
Total capital
$412M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$412M
1 Form D · last Apr 2018
102 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
15
25 pending · first 2023
Rank in peer group#100 of 1449

Capital timeline

2018FEDERAL ↑EQUITY ↓Cumulative $412M1st Form D$412M
2018FEDERAL ↑EQUITY ↓Cumulative $412M1st Form D$412M

Latest events

  • Private capital raisedForm D · SEC · 1st filing$412M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 1449 peers

Line = median

Biotech · Molecule

  • Granted patents#100 · top 7%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings
  • ARIE M. BELLDEGRUNDirectorNamed in SEC Form D filings
  • DAVID M. BONDERMANDirectorNamed in SEC Form D filings
  • DAVID M. CHANGDirectorNamed in SEC Form D filings
  • DAVID M. TANENExecutive OfficerNamed in SEC Form D filings
  • FRANZ M. HUMERDirectorNamed in SEC Form D filings
  • JOHN M. DEYOUNGDirectorNamed in SEC Form D filings
Show all 10 people
  • JOSHUA A. KAZAMExecutive Officer, DirectorNamed in SEC Form D filings
  • OWEN M. WITTEDirectorNamed in SEC Form D filings
  • ROBERT M. ABRAHAMDirectorNamed in SEC Form D filings
  • TODD M. SISITSKYDirectorNamed in SEC Form D filings

What it has protected

USPTO · 15 granted of 40
  • PendingMETHODS FOR ENHANCING TCRab+ CELL DEPLETION EFFICIENCYUSPTOApplication 19572670
  • PendingChimeric Cytokine Receptors Comprising Tgf Beta Binding DomainsUSPTOApplication 19429975
  • PendingChimeric Cytokine Receptors Bearing A PD-1 EctodomainUSPTOApplication 19551160
Show all 40 patent records
  • NEUMEDICINES, INC.Similar federal contract value in Biotech · null in contracts
  • Zura Bio LtdSimilar federal contract value in Biotech · null in contracts
  • Galecto, Inc.Similar federal contract value in Biotech · null in contracts
  • RayzeBioSimilar federal contract value in Biotech · null in contracts
  • ImvaxSimilar federal contract value in Biotech · null in contracts
  • Zenas BioPharmaSimilar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .